A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects After Multiple Oral Doses of TAK-058
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2017
At a glance
- Drugs TAK 058 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Takeda
- 09 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Nov 2015 Treatment arms changed from 4 to 5 as reported by ClinicalTrials.gov record.
- 17 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.